{"schema":"hottub-news/prospects/v1","item":{"id":"n_2jy5dreypqi27xmsoopq","title":"El pertuzumab de Biocon recibe la autorización de comercialización en la UE. Primer biosimilar autorizado mediante el nu","title_en":null,"url":"https://www.europapress.es/comunicados/internacional-00907/noticia-comunicado-pertuzumab-biocon-recibe-autorizacion-comercializacion-ue-primer-biosimilar-autorizado-nu-20261118152217.html","outlet":"Europa Press","published":"2026-11-18T14:22:00Z","sponsored":false,"page":"https://hottub.news/articles/n_2jy5dreypqi27xmsoopq"},"prospects":[{"name":"Europa Press","kind":"organization","role":"outlet","website":"https://europapress.es/","entity":"wikidata:Q3060712","source":"https://www.europapress.es/comunicados/internacional-00907/noticia-comunicado-pertuzumab-biocon-recibe-autorizacion-comercializacion-ue-primer-biosimilar-autorizado-nu-20261118152217.html","note":"Published: El pertuzumab de Biocon recibe la autorización de comercialización en la UE. Primer biosimilar autorizado mediante el nu (2026-11-18)","reason":"Published “El pertuzumab de Biocon recibe la autorización de comercialización en la UE. Primer biosimilar autorizado mediante el nu” on 2026-11-18","group":"Outlet","add_url":"https://crm.joinhottub.com/relationships/add#name=Europa%20Press&kind=organization&website=https%3A%2F%2Feuropapress.es%2F&source=https%3A%2F%2Fwww.europapress.es%2Fcomunicados%2Finternacional-00907%2Fnoticia-comunicado-pertuzumab-biocon-recibe-autorizacion-comercializacion-ue-primer-biosimilar-autorizado-nu-20261118152217.html&entity=wikidata%3AQ3060712&note=Published%3A%20El%20pertuzumab%20de%20Biocon%20recibe%20la%20autorizaci%C3%B3n%20de%20comercializaci%C3%B3n%20en%20la%20UE.%20Primer%20biosimilar%20autorizado%20mediante%20el%20nu%20%282026-11-18%29","propose":{"name":"Europa Press","kind":"organization","reason":"Published “El pertuzumab de Biocon recibe la autorización de comercialización en la UE. Primer biosimilar autorizado mediante el nu” on 2026-11-18","requestId":"news:n_2jy5dreypqi27xmsoopq:wikidata:Q3060712:deb5eac0","website":"https://europapress.es/","sourceUrl":"https://www.europapress.es/comunicados/internacional-00907/noticia-comunicado-pertuzumab-biocon-recibe-autorizacion-comercializacion-ue-primer-biosimilar-autorizado-nu-20261118152217.html","entity":"wikidata:Q3060712"}}],"someone_else":{"source":"https://www.europapress.es/comunicados/internacional-00907/noticia-comunicado-pertuzumab-biocon-recibe-autorizacion-comercializacion-ue-primer-biosimilar-autorizado-nu-20261118152217.html","note":"In the news: El pertuzumab de Biocon recibe la autorización de comercialización en la UE. Primer biosimilar autorizado mediante el nu (Europa Press, 2026-11-18)"},"crm":{"name":"CRM by Hottub","add":"Open add_url in a browser: CRM by Hottub's add form, filled in. Nothing is saved until the person presses Add.","mcp":"https://crm.joinhottub.com/api/crm/mcp","tool":"propose_relationship","propose":"If you're connected to CRM by Hottub's MCP server with proposal access, call propose_relationship with `propose` as its arguments. An owner approves it before anything is added. Keep the arguments as given: retries reuse requestId."}}